Caris Life Sciences, Inc. (NASDAQ: CAI)

Caris Life Sciences, Inc. is a patient centric AI driven TechBio company that develops and commercializes precision medicine solutions using comprehensive molecular information and artificial intelligence/machine learning at scale. The company focuses on oncology, offering tissue and blood based genomic profiling services that support early detection, minimal residual disease monitoring, therapy selection, and treatment monitoring. Its proprietary platform integrates next generation sequencing, AI/ML, and high performance computing to generate one of the largest multimodal clinico genomic datasets in cancer.

Caris Life Sciences generates revenue primarily from the sale of its molecular profiling tests and related services to physicians, hospitals, academic centers, and biopharma companies. It also earns income through data licensing agreements that provide deidentified multi modal datasets to external researchers and pharmaceutical partners. Additionally, the company derives revenue from collaborative research and development arrangements with biopharma firms that aim to discover and develop novel therapeutics using its platform.

The company operates through the following segments.

• Molecular Intelligence: This segment provides comprehensive tumor and liquid biopsy profiling, including whole exome, whole transcriptome, and whole genome sequencing solutions such as MI Profile, Caris Assure, and the Precision Whole Genome platform, which support cancer detection, treatment selection, and monitoring.

• Caris Discovery: This segment focuses on drug target and therapeutic discovery, leveraging the company’s profiling data, wet lab facilities, AI/ML tools, and the ADAPT platform to identify novel drug targets and develop therapeutics in partnership with biopharma companies.

• Caris Strategic Data: This segment licenses deidentified multi modal clinico genomic datasets to external researchers and pharmaceutical companies, enabling drug discovery, translational research, and clinical trial design through AI driven analytics.

• Caris Infrastructure: This segment encompasses the company’s laboratory, research, and sales infrastructure, including high throughput sequencing facilities in Phoenix and Tempe, which support scalable testing operations and commercial expansion.

Caris Life Sciences holds a strong position in the precision oncology market, competing with established players such as Foundation Medicine (Roche), Tempus, Guardant Health, and Natera in tissue and liquid biopsy profiling. The company differentiates itself through its patient first approach that delivers deep whole exome and whole transcriptome sequencing, providing industry leading breadth, depth, and accuracy of multi omic information. Its competitive advantages include a large and growing multi modal clinico genomic dataset, a specialized commercial team serving over 6,000 ordering physicians, robust laboratory infrastructure, and deep collaborations with academic centers and biopharma partners.

Caris Life Sciences serves a diverse customer base that includes treating physicians, hospitals, academic cancer centers, and biopharma companies such as Moderna, AbbVie, Xencor, Merck KGaA, and Genentech. The company also works with the members of its Precision Oncology Alliance, a network of leading cancer research institutions, and provides services to over 6,000 ordering physicians across the United States.